henhaobio
Sign in

Genomics Proteomics & BioinformaticsBioinformaticsPeer-reviewed journal article

TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource

Zhihang CheniD, Ziwei LuoiD, Di ZhangiD, Huiqin LiiD, Xuefei LiuiD, Kaiyu ZhuiD, Hongwan ZhangiD, Zongping WangiD, Penghui ZhouiD, Jian Min ReniD, An ZhaoiD, Zhixiang ZuoiD

PDFDOIPreprint

Abstract

Immunotherapy is a promising cancer treatment method, but only a few patients benefit from it. Developing new immunotherapy strategies and effective biomarkers of response and resistance is urgent. Recent high-throughput bulk and single-cell gene expression profiling technologies have generated valuable resources in these regards. However, these resources are not well organized and systematic analysis is difficult. Here, we present TIGER, a tumor immunotherapy gene expression resource, which contains bulk transcriptome data of 1508 tumor samples with immunotherapy clinical outcome and 11,057 tumor/normal samples without immunotherapy clinical outcome, as well as single-cell transcriptome data of 2,116,945 immune cells of 655 samples. TIGER provides many useful modules to analyze the collected data and user-provided data. Using the resource in TIGER, we identified a tumor enriched subset of CD4+ T cells. Melanoma patients with higher signature score of this subset have significantly better response and survival under immunotherapy. We believe that TIGER will be helpful for understanding anti-tumor immunity mechanisms and discovering effective biomarkers. TIGER is freely accessible at http://tiger.canceromics.org/.

Citations
122
FWCI
10.56
Field percentile
top 1%

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISGivechian '18Lin '22Danaher '16Sun '20Kus '25Miao '20
67% semantic matchCancer Biology
K. B. Givechian, K. Wnuk, C. Garner+5 more·bioRxiv·Jan 11, 2018